Last updated: July 27, 2026

Application No. 18/308,894

METHODS OF TREATING AGING-RELATED DISORDERS

Final Rejection

Filed

Apr 28, 2023

Priority

Aug 30, 2018 — provisional 62/725,038 +13 more

Examiner

SKELDING, ZACHARY S

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

ImmunityBio Inc.

OA Round

2 (Final)

This examiner grants 60% of cases after interview

— +41.4% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 828 resolved cases, 2023–2026

Examiner Intelligence

SKELDING, ZACHARY S View full profile →

Grants 60% of resolved cases

Career Allowance Rate

494 granted / 828 resolved

At TC average

Strong +41% interview lift

Without

With

+41.4%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

41 currently pending

Career history

861

Total Applications

across all art units

Statute-Specific Performance

§101

1.8%

-38.2% vs TC avg

§103

32.7%

-7.3% vs TC avg

§102

10.0%

-30.0% vs TC avg

§112

35.0%

-5.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 828 resolved cases

Prosecution Timeline

Apr 28, 2023

Application Filed

Apr 08, 2026

Non-Final Rejection mailed

May 22, 2026

Response Filed

Jul 17, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/310,141

Patent 12673981

T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS

3y 2m to grant Granted Jul 07, 2026

17/774,333

Patent 12668641

ANTIBODY VARIANT COMBINATIONS AND USES THEREOF

4y 1m to grant Granted Jun 30, 2026

18/066,791

Patent 12655218

IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS

3y 6m to grant Granted Jun 16, 2026

18/174,928

Patent 12630802

METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD

3y 2m to grant Granted May 19, 2026

17/791,056

Patent 12617860

ANTI-TNFR2 ANTIBODY AND USES THEREOF

3y 10m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

60%

Grant Probability

99%

With Interview (+41.4%)

3y 7m (~4m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 828 resolved cases by this examiner. Grant probability derived from career allowance rate.